Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Recall test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    194 result(s) found for: Recall test. Displaying page 7 of 10.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    EudraCT Number: 2009-011523-31 Sponsor Protocol Number: 09/H0720/64 Start Date*: 2009-06-23
    Sponsor Name:R & D, Cambridge University Hospitals
    Full Title: A study of the immune response to vaccination in MS patients treated with alemtuzumab
    Medical condition: The vaccinations are being used to investigate immunological memory following treatment of multiple sclerosis with the lympho-depleting humanised monoclonal antibody alemtuzumab.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063399 Relapsing-remitting multiple sclerosis PT
    9.1 10063400 Secondary progressive multiple sclerosis PT
    9.1 10046859 Vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-000934-38 Sponsor Protocol Number: CP-BR-1-2007 Start Date*: 2007-10-30
    Sponsor Name:Generex Biotechnology Corporation
    Full Title: Prospective, Randomized, Single-Blinded, Multi-Center Phase II Trial of the HER2/neu Peptide GP2 + GM-CSF Vaccine versus GM-CSF Alone in HLA-A2+ OR the Modified HER2/neu Peptide AE37 + GM-CSF Vacci...
    Medical condition: Disease-free, conventionally treated node-positive and high-risk node-negative breast cancer patients who are at significant risk for recurrence.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006187 Breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-014734-16 Sponsor Protocol Number: B0541004 Start Date*: 2010-01-04
    Sponsor Name:Pfizer Limited, Ramsgate Road, Sandwich, Kent CT13 9NJ
    Full Title: A PHASE 2A RANDOMIZED, DOUBLE-BLINDED, DOUBLE DUMMY, PLACEBO AND ACTIVE CONTROLLED, TWO-WAY CROSS-OVER, FLARE-ENRICHED MULTI-CENTRE CLINICAL TRIAL TO EXAMINE THE PAIN RELIEF PRODUCED BY 2 WEEKS OF ...
    Medical condition: OSTEOARTHRITIS OF THE KNEE
    Disease: Version SOC Term Classification Code Term Level
    12.0 10023476 Knee osteoarthritis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2019-001899-11 Sponsor Protocol Number: C1701-202 Start Date*: 2019-11-07
    Sponsor Name:Cyclerion Therapeutics, Inc.
    Full Title: A Randomized, Placebo-controlled, Phase 2 Study to Evaluate the Safety and Pharmacodynamics of Once-daily Oral IW-1701 in Patients with Stable Sickle Cell Disease
    Medical condition: Stable Sickle Cell Disease (SCD)
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2004-004350-91 Sponsor Protocol Number: TAK-375/EC301 Start Date*: 2005-11-10
    Sponsor Name:Takeda Europe R&D Centre Ltd
    Full Title: A multicentre, randomised, double-blind, double-dummy, placebo-controlled study to evaluate the safety and efficacy of ramelteon compared to placebo with zopiclone as a reference arm in adults with...
    Medical condition: chronic insomnia
    Disease: Version SOC Term Classification Code Term Level
    8 10053851 LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) AT (Completed) FI (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-004043-21 Sponsor Protocol Number: 16-OBE2109-016 Start Date*: 2018-10-17
    Sponsor Name:ObsEva SA
    Full Title: An exploratory, single centre, open label, pilot study investigating the efficacy and safety of OBE2109 200 mg daily For 12 weeks followed by 100 mg daily for 12 weeks in rectovaginal endometriosis.
    Medical condition: Rectovaginal endometriosis
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2007-006305-25 Sponsor Protocol Number: 2007-006305-25 Start Date*: 2008-02-15
    Sponsor Name:Karolinska University Hospital
    Full Title: Effects of rimonabant (Acomplia) on obesity in adults with Prader-Willi Syndrome
    Medical condition: Obese adults with Prader Willi Syndrome
    Disease: Version SOC Term Classification Code Term Level
    9.1 10036476 Prader-Willi syndrome LLT
    9.1 10029883 Obesity LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003555-77 Sponsor Protocol Number: IB-2008-01 Start Date*: Information not available in EudraCT
    Sponsor Name:Boiron
    Full Title: Evaluation de l'intérêt d'associer un traitement homéopathique à la prise en charge anti-émétique conventionnelle dans la prévention des nausées retardées lors des deux premières cures de chimioth...
    Medical condition: Nausées retardées lors de la prise en charge des cancers thoraciques par chimiothérapie hautement émétisante (a base de Cisplatine).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10056989 Nausea post chemotherapy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-012198-36 Sponsor Protocol Number: NTx-RTx-LD-001 Start Date*: 2010-01-12
    Sponsor Name:Universitätsklinikum Giessen und Marburg - Standort Giessen
    Full Title: Einfluss von Rituximab-Induktion und Lebendspende auf Immunregulation und Viruskontrolle nach Nierentransplantation - eine prospektive Pilotstudie
    Medical condition: Living donor and deceased donor kidney transplantation. ABO compatible and ABO incompatible kidney transplantation.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-003630-33 Sponsor Protocol Number: ERGO45359 Start Date*: 2019-01-23
    Sponsor Name:University of Southampton
    Full Title: Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe p...
    Medical condition: Acne of sufficient severity to warrant treatment with oral antibiotics.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10040785 - Skin and subcutaneous tissue disorders 10000496 Acne PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2021-003471-34 Sponsor Protocol Number: REN001-202 Start Date*: 2022-04-19
    Sponsor Name:Reneo Pharma Ltd.
    Full Title: AN OPEN-LABEL, MULTI-CENTRE STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF REN001 IN SUBJECTS WITH PRIMARY MITOCHONDRIAL MYOPATHY (PMM)
    Medical condition: Primary Mitochondrial Myopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10027710 Mitochondrial myopathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) ES (Prematurely Ended) DK (Prematurely Ended) BE (Completed) HU (Prematurely Ended) NL (Ongoing) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000860-90 Sponsor Protocol Number: CRAD001M2304 Start Date*: 2013-02-14
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A three-arm, randomized, double-blind, placebo-controlled study of the efficacy and safety of two trough-ranges of everolimus as adjunctive therapy in patients with tuberous sclerosis complex (TSC)...
    Medical condition: Refractory partial-onset seizures associated with tuberous sclerosis complex (TSC)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10010331 - Congenital, familial and genetic disorders 10045138 Tuberous sclerosis PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) NL (Completed) DE (Completed) HU (Completed) GB (Completed) BE (Completed) GR (Completed) DK (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2020-002063-60 Sponsor Protocol Number: PRN1008-018(EFC17093) Start Date*: 2020-11-12
    Sponsor Name:Principia Biopharma, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled, Parallel-Group Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Oral Rilzabrutinib (PRN1008) in Adults...
    Medical condition: Immune Thrombocytopenia (ITP)
    Disease: Version SOC Term Classification Code Term Level
    23.0 10005329 - Blood and lymphatic system disorders 10074667 Immune thrombocytopenic purpura LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) PL (Trial now transitioned) AT (Completed) NO (Trial now transitioned) FR (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022596-64 Sponsor Protocol Number: DRI10734 Start Date*: 2011-01-27
    Sponsor Name:sanofi-aventis recherche & développement
    Full Title: Estudio internacional, multicéntrico, aleatorizado, doble ciego, con grupos paralelos y controlado con placebo del efecto sobre la función cognitiva, la seguridad y la tolerabilidad de SAR110894D, ...
    Medical condition: Demencia tipo enfermedad de Alzheimer_______________ Dementia Alzheimer's type
    Disease: Version SOC Term Classification Code Term Level
    12.1 10012271 Dementia Alzheimer's type LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) PT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002147-34 Sponsor Protocol Number: AZT-001 Start Date*: 2016-01-21
    Sponsor Name:AZTherapies, Inc.
    Full Title: A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease.
    Medical condition: Early stage of Alzheimer's Disease.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2017-001724-22 Sponsor Protocol Number: GA39688 Start Date*: 2017-12-21
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, PLACEBO-CONTROLLED CLINICAL TRIAL OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
    Medical condition: Chronic rhinosinusitis with nasal polyps
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) CZ (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2008-001153-17 Sponsor Protocol Number: 262 Start Date*: 2008-06-16
    Sponsor Name:MSD
    Full Title: Phase III (Phase V Program), Open-Label, Randomized, Referred- Care-Controlled, Clinical Trial to Evaluate the Efficacy and Safety of MK-0217A/Alendronate Sodium 70 mg/Vitamin D3 5600 I.U. Combinat...
    Medical condition: Postmenopausal women with osteoporosis at increased risk of falls.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10031285 Osteoporosis postmenopausal LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Completed) DE (Completed) ES (Completed) LT (Completed) GB (Completed) BE (Completed) LV (Completed) FR (Completed) IE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-003675-61 Sponsor Protocol Number: D3252C00001 Start Date*: 2017-12-21
    Sponsor Name:AstraZeneca AB
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase 3 Efficacy and Safety Study Of Benralizumab in Patients with Severe Nasal Polyposis
    Medical condition: Nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004855 10028754 Nasal polyp LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed) AT (Completed) BE (Completed) HU (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-001166-26 Sponsor Protocol Number: M13-813 Start Date*: 2015-12-28
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor R...
    Medical condition: Newly diagnosed glioblastoma (GBM) or gliosarcoma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006153 Brain tumor LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) NL (Completed) IE (Completed) DE (Completed) BE (Completed) AT (Completed) GB (GB - no longer in EU/EEA) PT (Completed) ES (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2016-000108-27 Sponsor Protocol Number: H8A-MC-LZBE Start Date*: 2016-08-25
    Sponsor Name:Eli Lilly and Company
    Full Title: A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal Alzheimer’s Disease
    Medical condition: Prodromal Alzheimer’s Disease
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10012271 Dementia Alzheimer's type PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 2  3  4  5  6  7  8  9  10  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 06:41:29 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA